Literature DB >> 11087577

Solid-phase synthesis and biological evaluation of a combinatorial library of philanthotoxin analogues.

K Strømgaard1, T J Brier, K Andersen, I R Mellor, A Saghyan, D Tikhonov, P N Usherwood, P Krogsgaard-Larsen, J W Jaroszewski.   

Abstract

The modular structure of philanthotoxins was exploited for construction of the first combinatorial library of these compounds using solid-phase parallel synthesis. (S)-Tyrosine and (S)-3-hydroxyphenylalanine were used as amino acid components, spermine, 1,12-dodecanediamine, and 4,9-dioxa-1,12-dodecanediamine as amine components, and butanoyl, phenylacetyl, and cyclohexylacetyl as N-acyl groups. Following automated preparative HPLC, the resulting 18 compounds were isolated as the S-forms in 40-70% yields. The purity of the products was determined by HPLC with evaporative light scattering detection and by (1)H and (13)C NMR. The thus obtained philanthotoxins were tested electrophysiologically for their antagonist properties on human muscle-type nicotinic acetylcholine receptors (nAChR) expressed in TE671 cells and on rat brain non-NMDA glutamate receptors (non-NMDAR) expressed in Xenopus oocytes. 4-Hydroxy analogues lacking the secondary amino groups (PhTX-12 and 4,9-dioxa-PhTX-12 and their analogues) were inactive on non-NMDAR, whereas the potency of the spermine derivatives (PhTX-343 and its analogues) increased with steric bulk of the N-acyl group. The analogue of PhTX-343 in which the N-butanoyl group was replaced by phenylacetyl group had IC(50) of 15 +/- 4 nM on non-NMDAR. Increasing the steric bulk of the N-acyl group was not advantageous for activity at nAChR, and a sharp decrease in potency with increased steric bulk was observed with the derivatives of PhTX-12. 3-Hydroxy analogues generally exhibited lower activity and different response to alterations of the N-acyl groups as compared to the 4-hydroxy analogues. Since the acyl group alterations in PhTX-343 and 4,9-dioxa-PhTX-12 have a similar effect on potency, which is distinctly different from that observed for PhTX-12, the two former compounds may bind to nAChR in a similar fashion but differently from that of PhTX-12. The combinatorial library approach described in this work represents a prototype methodology for future exploration of structure-activity relationships of philanthotoxins.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11087577     DOI: 10.1021/jm000220n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Polyamine regulation of ion channel assembly and implications for nicotinic acetylcholine receptor pharmacology.

Authors:  Madhurima Dhara; Jose A Matta; Min Lei; Daniel Knowland; Hong Yu; Shenyan Gu; David S Bredt
Journal:  Nat Commun       Date:  2020-06-03       Impact factor: 14.919

2.  The Effects of Structural Alterations in the Polyamine and Amino Acid Moieties of Philanthotoxins on Nicotinic Acetylcholine Receptor Inhibition in the Locust, Schistocerca gregaria.

Authors:  Victoria L Luck; David P Richards; Ashif Y Shaikh; Henrik Franzyk; Ian R Mellor
Journal:  Molecules       Date:  2021-11-19       Impact factor: 4.411

3.  Neuroactive compounds obtained from arthropod venoms as new therapeutic platforms for the treatment of neurological disorders.

Authors:  Victoria Monge-Fuentes; Flávia Maria Medeiros Gomes; Gabriel Avohay Alves Campos; Juliana de Castro Silva; Andréia Mayer Biolchi; Lilian Carneiro Dos Anjos; Jacqueline Coimbra Gonçalves; Kamila Soares Lopes; Márcia Renata Mortari
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2015-08-08

4.  New Analogs of Polyamine Toxins from Spiders and Wasps: Liquid Phase Fragment Synthesis and Evaluation of Antiproliferative Activity.

Authors:  Christos Vassileiou; Stefania Kalantzi; Eleanna Vachlioti; Constantinos M Athanassopoulos; Christos Koutsakis; Zoi Piperigkou; Nikos Karamanos; Theodora Stivarou; Peggy Lymberi; Konstantinos Avgoustakis; Dionissios Papaioannou
Journal:  Molecules       Date:  2022-01-10       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.